StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Calquence (acalabrutinib) — US product sales by Quarter

Calquence (acalabrutinib) — US product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Calquence (acalabrutinib) — US product sales: $687M in Q2 2026, up 17.8% from a year earlier. That is the highest of the 23 quarters on record here.

Latest, Q2 2026
687
Period ended Jun 30, 2026
Change on a year earlier
+17.8%
583 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Calquence | | 1,022 | | 17 | | 16 | | 687 | | 18 | | 67 | | 36 | | 30 | | 225 | | 13 | | 9 | | 43 | | 3 | | 3”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCalquence (acalabrutinib) — US product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026687+17.8%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026599+18.1%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025637+11.2%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025612+7.4%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025583+5.2%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025507+2.6%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024573+19.9%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024570+21.8%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024554+14.2%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024494+28.6%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023478+2.8%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023468+2.4%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023485+22.5%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023384+13.3%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022465+38.4%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022457+48.4%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up calquence (acalabrutinib) — US product sales

Cite this data

StockData. (2026). AstraZeneca Calquence (acalabrutinib) — US product sales ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-calquence-us

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.